Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer

Launched by M.D. ANDERSON CANCER CENTER · Dec 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new tool called the INPUT Screening Tool, which aims to help patients with metastatic or incurable lung cancer better understand their illness. The goal is to find out if asking patients about their information needs, preferences, and understanding of their condition, and sharing this information with their doctors, can lead to clearer discussions about their health and treatment options. This could help patients feel more informed and involved in their care.

To participate in this study, you need to be at least 18 years old and have been diagnosed with metastatic or incurable lung cancer within the last three months. You should also be able to speak English and plan to attend a follow-up visit at the MD Anderson cancer center for treatment. If you have any cognitive impairments, this trial may not be suitable for you. If you join, you can expect to have conversations with healthcare providers that focus on your specific questions and concerns, which may help you feel more confident about your treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Within 3 months of biopsy-confirmed diagnosis of stage IV lung cancer
• • Age 18 or over
• • English speaking
• • Attending a follow-up visit at the thoracic medical oncology clinic
• • Plans to receive or actively undergoing cancer-directed systemic treatment at MD Anderson
• Exclusion Criteria:
• • • Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker